SAM
TGTX icon

Smartleaf Asset Management’s TG Therapeutics TGTX Stock Holding History

Smartleaf Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.5K Hold
1,517
– – ﹤0.01% 1256
2026
Q1 		$47.8K Sell
1,517
-1,630
-52% -$48.6K ﹤0.01% 1472
2025
Q4 		$93.6K Buy
3,147
+454
+17% +$14.8K ﹤0.01% 1223
2025
Q3 		$99.2K Buy
2,693
+467
+21% +$15.4K 0.01% 1078
2025
Q2 		$81.7K Sell
2,226
-190
-8% -$7.07K 0.01% 945
2025
Q1 		$96.3K Buy
2,416
+511
+27% +$17.2K 0.01% 848
2024
Q4 		$59.9K Buy
1,905
+1,594
+513% +$45.7K 0.01% 1096
2024
Q3 		$7.41K Buy
311
+63
+25% +$1.38K ﹤0.01% 1933
2024
Q2 		$4.45K Buy
248
+215
+652% +$3.43K ﹤0.01% 1860
2024
Q1 		$513 Buy
+33
New +$526 ﹤0.01% 1735

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Smartleaf Asset Management's TGTX Position: Q2 2026 in Review

Smartleaf Asset Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 1,517 shares worth $84.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

Smartleaf Asset Management first reported a position in TGTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $99.2K in Q3 2025. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Smartleaf Asset Management held 1,517 shares of TG Therapeutics worth $84.5K as of Q2 2026.
  • Smartleaf Asset Management left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1256 holding.
  • Smartleaf Asset Management first reported a position in TG Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Smartleaf Asset Management's TG Therapeutics position peaked at $99.2K in Q3 2025.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.